<DOC>
	<DOCNO>NCT02456701</DOCNO>
	<brief_summary>This patient pilot study test hypothesis vemurafenib addition KTN3379 restore iodine incorporation BRAF mutant ( MUT ) , radioiodine-refractory ( RAIR ) thyroid cancer patient .</brief_summary>
	<brief_title>Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With Combination Vemurafenib KTN3379</brief_title>
	<detailed_description>This patient pilot study test hypothesis vemurafenib addition KTN3379 restore iodine incorporation BRAF mutant ( MUT ) , radioiodine-refractory ( RAIR ) thyroid cancer patient . Eligible patient BRAF MUT , RAIR thyroid cancer undergo human recombinant TSH ( rhTSH Thyrogen ) -stimulated 124I PET/CT lesional dosimetry quantify baseline RAI avidity index metastatic lesion ( ) . Patients receive vemurafenib follow addition KTN3379 second Thyrogen-stimulated 124I PET/CT lesional dosimetry perform . For patient whose tumor ( ) demonstrate sufficient iodine incorporation warrant 131I therapy , Thyrogen-stimulated standard dosimetry perform therapeutic 131I administer concurrently vemurafenib KTN3379 . Subsequent discontinuation vemurafenib , tumor assessment conduct serial radiologic scan ( ) thyroglobulins ( scan perform baseline , 131I , 3 month ( +/- 1 month ) follow 131I , 6 month 131I ) .</detailed_description>
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<criteria>Patients must histologically cytologically confirm thyroid carcinoma follicular origin ( include papillary , follicular , poorly differentiate subtypes respective variant ) . Confirmation CLIA certify laboratory FDAapproved assay one patient 's thyroid tumor ( primary tumor , recurrent tumor , metastasis ) possess BRAF mutation V600 . Patients must measurable disease define RECIST criterion 1.1 . Tumors previously irradiate field may consider measureable evidence tumor progression radiation treatment . RAIrefractory disease structural imaging Age ≥ 18 year . ECOG performance status ≤ 2 Patients must normal organ marrow function define : Absolute neutrophil count ( ANC ) &gt; 1.5x109/L Hemoglobin ≥ 9 g/dL Platelets ≥ 100 x 109/L Albumin ≥ 2.5 g/dL Total bilirubin ≤ 1.5x institutional ULN Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 2x institutional ULN unless related primary disease Creatinine ≤ 1.5 mg/dL OR calculate creatinine clearance ( CockcroftGault formula ) ≥ 50 mL/min OR 24hour urine creatinine clearance ≥ 50 mL/min Concomitant malignancies previous malignancy treat within past 3 year . Exception : Patients diseasefree 3 year , patient history completely resect nonmelanoma skin cancer , and/or patient indolent secondary malignancy , eligible . Use investigational drug within 28 day precede first dose vemurafenib study . Symptomatic untreated leptomeningeal brain metastasis spinal cord compression . History evidence cardiovascular risk include follow : Corrected QT ( QTc ) interval ≥ 450 msec baseline history congenital long QT syndrome uncorrectable electrolyte abnormality . ( Patients well control atrial fibrillation exempt criterion . ) History cerebrovascular attack transient ischemic attack within 6 month prior initiation therapy protocol . Uncontrolled intercurrent illness include , limited , ongoing active infection psychiatric illness/social situation would limit compliance study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>